[P1.176] Ingested (oral) Tocilizumab Inhibits EAE
Staley Brod,1Victoria Bauer2,1
1Houston, TX, USA, 2
BACKGROUND: Ingested immunoactive proteins type I IFN, SIRS peptide 1-21, α-MSH, ACTH, SST inhibit clinical attacks and inflammation in acute EAE.
OBJECTIVE: We examined whether an antibody against IL-6, tocilizumab (TCZ) (Actemra®), used clinically in rheumatoid arthritis (RA) would have similar anti-inflammatory effects in EAE after oral administration.
DESIGN/METHODS: B6 mice were immunized with MOG peptide 35-55 and gavaged with control saline or TCZ during ongoing disease. Splenocytes, CD4+ T cells or macrophages/monocyte lineage cells (CD11b+) from control fed or TCZ fed mice were adoptively transferred into active MOG peptide 35-55 immunized recipient mice during ongoing disease. Actively fed and recipient mice were examined for disease inhibition, inflammation, and cytokine responses.
RESULTS: Ingested (oral) TCZ inhibited ongoing disease and decreased inflammation. Adoptively transferred cells from TCZ fed donors protected against actively induced disease and decreased inflammation. There was a decrease in TNF-α, Th1-like cytokine IL-12 and increase in Th2-like cytokine IL-10 in active fed and adoptively treated recipients.
CONCLUSIONS: Ingested (orally administered) TCZ can inhibit clinical disease, CNS inflammation, decrease pro-inflammatory Th1-like cytokines and increase Th2-like anti-inflammatory cytokines.
Category - MS and CNS Inflammatory Disease: Basic Science
Monday, April 28, 2014 3:00 PM
P1: Poster Session I: CNS and Disease Mechanisms in Humans and Animal Models (3:00 PM-6:30 PM)